reflecting challenging macro demand trends in China. Competitive Headwinds: Considering QIAGEN’s huge gamut of services, the company is facing increasing competition from firms that provide ...

reflecting challenging macro demand trends in China. Recording more than 50% of its revenues from the international market, QIAGEN is highly exposed to the risk of foreign currency movement.

China, as you know, Qiagen has a small or relatively small exposure to China, it’s between 5% and 6% of our business. We always said over the last three years, that we do not believe that the ...

QIAGEN (Suzhou) Translational Medicine Co. (TMC) Ltd. is the first diagnostic R&D company focused on translational science in China. The company provides complete solutions for precision medicine ...

QIAGEN has announced the official opening of a new data center in Melbourne, Australia, designed to strengthen its global bioinformatics leadership position in this region of the world.

QIAGEN announced earlier in January plans for the repurchase, which comes after QIAGEN returned approximately $300 million to shareholders in early 2024 also through a synthetic share repurchase.

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks ...